Abstract Introduction: Acquired hemophilia A (AHA) is a rare autoimmune hemorrhagic disorder characterized by neutralizing autoantibodies against coagulation factor VIII (FVIII). First-line immunosuppressive therapy with corticosteroids with or without rituximab achieves complete remission (CR) in 60-80% of patients; however, relapse occurs in approximately 15-33% of cases after treatment cessation.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Yabei
Contact Yabei, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack